{"id":7571,"date":"2025-12-08T08:00:20","date_gmt":"2025-12-08T07:00:20","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=congress-resource&#038;p=7571"},"modified":"2025-12-08T13:57:23","modified_gmt":"2025-12-08T12:57:23","slug":"progression-free-survival-in-patients-with-low-hrqol-treated-with-zanubrutinib-vs-ibrutinib-in-rr-cll-sll","status":"publish","type":"congress-resource","link":"https:\/\/beonemedaffairs.com\/us\/congress-resource\/7571\/progression-free-survival-in-patients-with-low-hrqol-treated-with-zanubrutinib-vs-ibrutinib-in-rr-cll-sll\/","title":{"rendered":"Progression-free survival (PFS) in patients with low health-related quality of life (HRQoL) treated with zanubrutinib versus ibrutinib monotherapy: Post hoc analysis of the ALPINE trial"},"content":{"rendered":"","protected":false},"template":"","post-tag":[559,760,704,673,628,594,656,622,654,849,542],"class_list":["post-7571","congress-resource","type-congress-resource","status-publish","hentry","post-tag-alpine","post-tag-american-society-of-hematology","post-tag-ash","post-tag-btk-inhibitor","post-tag-btki","post-tag-chronic-lymphocytic-leukemia","post-tag-cll","post-tag-health-related-quality-of-life","post-tag-hrqol","post-tag-relapsed-refractory-cll","post-tag-zanubrutinib","congress_resource_type-poster","content_type-reading","molecule-zanubrutinib"],"acf":{"congress_resource_url_override":"ash-2025","congress":6819,"category":245,"prioritization":0,"key_data_presentation":false,"key_data_presentation_only":false,"key_data_presentation_prioritization":0,"tags":[704,760,656,594,849,559,654,622,542,628,673],"visible_tags":[704,542,654],"content-type":246,"summary":"","text_app":"&nbsp;\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","text":"&nbsp;\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","table_heading":"","table":null,"faq_heading":"FREQUENTLY ASKED QUESTIONS","faq":null,"button_alt_link":"","no_post_image_preview":true,"download_file_reading":"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_pfs-in-patients-with-low-hrqol-treated-with-zanubrutinib-vs-ibrutinib-in-rr-cll-sll.pdf","display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","vimeo_url":"","videolange":null,"fliphtml_link":"","use_pdf_instead_of_fliphtml":false,"congress_resource_abstract_link":"","congress_resource_cta_label":"See abstract","congress_resource_cta_link":"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/293266","authors":[4613],"field_page_schema_override":[{"field_page_schema_override_type":"PresentationDigitalDocument","field_page_schema_override_data":"{\r\n  \"@type\": \"PresentationDigitalDocument\",\r\n  \"name\": \"Progression-free survival (PFS) in patients with low health-related quality of life (HRQoL) treated with zanubrutinib versus ibrutinib monotherapy: Post hoc analysis of the ALPINE trial \u2013 BeOne Medical Affairs | US\", \r\n  \"description\": \"Explore the ASH 2025 poster of a post-hoc analysis of PFS in patients with low HRQoL treated with zanubrutinib vs ibrutinib in R\/R CLL\/SLL by Loic Ysebaert et al.\",  \r\n  \"image\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/11\/ASH2025_pfs-in-patients-with-low-hrqol-treated-with-zanubrutinib-vs-ibrutinib-in-rr-cll-sll.jpeg\",\r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/progression-free-survival-in-patients-with-low-hrqol-treated-with-zanubrutinib-vs-ibrutinib-in-rr-cll-sll\/\",  \r\n  \"associatedMedia\": {\r\n    \"@type\": \"MediaObject\",\r\n    \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/293266\",\r\n    \"encodingFormat\": \"application\/pdf\"\r\n  },\r\n  \"datePublished\": \"2025-12-08\",  \r\n  \"keywords\": [\"alpine study\", \"post hoc analysis of alpine study\", \"alpine study zanubrutinib vs ibrutinib\", \"ALPINE post hoc data analysis\", \"zanubrutinib vs ibrutinib outcomes\"], \r\n  \"genre\": \"Poster\",   \r\n  \"author\": {\r\n    \"@type\": \"Person\",\r\n    \"name\": \"Loic Ysebaert, MD, PhD\"\r\n  },\r\n  \"publisher\": {\r\n    \"@type\": \"Organization\",\r\n    \"name\": \"BeOne Medicines\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/\"\r\n  },\r\n  \"about\": {\r\n    \"@type\": \"MedicalStudy\",\r\n    \"name\": \"Progression-free survival (PFS) in patients with low health-related quality of life (HRQoL) treated with zanubrutinib versus ibrutinib monotherapy: Post hoc analysis of the ALPINE trial\",  \r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/progression-free-survival-in-patients-with-low-hrqol-treated-with-zanubrutinib-vs-ibrutinib-in-rr-cll-sll\/\"\r\n  }\r\n}"},{"field_page_schema_override_type":"MedicalWebPage","field_page_schema_override_data":"{\r\n  \"@type\": \"MedicalWebPage\",   \r\n  \"name\": \"Progression-free survival (PFS) in patients with low health-related quality of life (HRQoL) treated with zanubrutinib versus ibrutinib monotherapy: Post hoc analysis of the ALPINE trial \u2013 BeOne Medical Affairs | US\",   \r\n  \"description\": \"Explore the ASH 2025 poster of a post-hoc analysis of PFS in patients with low HRQoL treated with zanubrutinib vs ibrutinib in R\/R CLL\/SLL by Loic Ysebaert et al.\",  \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/progression-free-survival-in-patients-with-low-hrqol-treated-with-zanubrutinib-vs-ibrutinib-in-rr-cll-sll\/\", \r\n  \"inLanguage\": \"en-US\",\r\n  \"@logo\": {\r\n    \"@type\": \"ImageObject\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/03\/BGI2404-BeOne-Primary-Logo-RGB-M04-V01-2.svg\"\r\n  }\r\n}"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource\/7571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/congress-resource"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/authors\/4613"},{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress\/6819"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/673"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/628"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/542"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/622"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/654"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/559"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/849"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/594"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/656"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/760"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/704"},{"embeddable":true,"taxonomy":"congress_resource_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress_resource_type\/245"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7571"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}